Biotech Markets on the move. June 2013

Biotech Markets on the move. June 2013

- Bluebird Bio raises $101M in upsized IPO. Opens at $25.50 (BLUE).
- Prosensa amends IPO and sets price range (RNA).
- FDA to review BLA from Pharming/Santarus.
- Exact Sciences raises $67.9M in follow-on.
- Royalty Pharma ends hostile bid for Elan.
- AstraZeneca and NGM Pharma sign deal to develop diabetes drugs.

[Read more...]

Biomarkets on the move. February 2013

Biomarkets on the move. February 2013

- Pozen presents positive Phase III data at stroke conference.
- GSK files MAA with EMA for trametinib as monotherapy and in combo with dabrafenib for metastatic melanoma.
- Addex Therapeutics to refocus pipeline, structure Geneva operations.
- Germany’s Federal Joint Committee says Vertex’s Kalydeco provides significant benefit.
- Acceleron’s eight Phase II trials.
- Lilly discontinues tabalumab for rheumatoid arthritis.
- €196 M pan-European drug discovery platform launched.
- Elan, Biogen Idec ink $3.25 B deal for MS drug Tysabri.

[Read more...]

Biomarkets on the move. January 2013

Biomarkets on the move. January 2013

- Celsion Phase III HEAT study fails.
- FDA to hold a public hearing on ALS on Feb 25.
- Genzyme/ISIS’ Kinamro to be priced at $176,000/year.
- Pharmaxis’ Bronchitol gets negative vote from FDA advisory committee.
- VC Edmond de Rothschild to raise $500 M over four years.
- Antibody company KaloBios preparing for IPO.
- Stemline jumps 18% on its first day of trading.

[Read more...]